Mounjaro offers up to 20% weight loss – but it’s not for everyone. Learn about eligibility, alternatives and why long-term ...

The Wegovy maker says the telehealth company didn't stop selling compounded versions of the blockbuster drug after Novo ...

Eli Lilly is looking to approach regulatory approval of efsitora alfa (efsitora), its once-weekly insulin for type 2 diabetes ...

Additional drug combinations may carry a risk of more side effects though, raising concerns from some doctors. Regeneron ...

Novo Nordisk has ended its partnership with Hims & Hers Health after two months, accusing the telehealth company of pushing ...

Novo Nordisk ends partnership with Hims & Hers over safety and marketing concerns tied to compounded Wegovy, as rivalry with ...

Shares of Hims & Hers Health Inc. (HIMS) slumped 29% on Monday morning after Danish drug maker Novo Nordisk (NVO) announced ...

The FDA had resolved the shortage of Wegovy in April, and telehealth providers were advised to stop selling compounded ...

Shares in Novo Nordisk fell as much as 3.5% on Monday after detailed trial data on its experimental obesity drug CagriSema ...

Novo Nordisk said Hims & Hers has “failed to adhere to the law which prohibits mass sales of compounded drugs” under the ...

A new injectable weight loss treatment from the maker of Ozempic and Wegovy delivered 23% weight loss in trials, according to ...

Novo Nordisk's new weight-loss drug helped patients lose even more weight on average than its current Wegovy blockbuster treatment, an early-stage trial showed, as the drugmaker races to develop the ...